Apyx Medical Corporation (APYX) — Financial statements
Income statement, balance sheet, and cash flow for Apyx Medical Corporation — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 53↑9.9% | 48↓8.1% | 52↑17.6% | 45↓8.3% | 49 | |
| Cost of Revenue | 34↑80.4% | 19↑0.8% | 19↑20.9% | 15↑3.1% | 15 | |
| Gross Profit | 19↓35.2% | 29↓13.0% | 34↑15.9% | 29↓13.3% | 34 | |
| Operating Expenses | ||||||
| R&D Expenses | 3↓33.6% | 5↑4.9% | 5↑6.6% | 5↑5.2% | 4 | |
| General & Administrative Expenses | 36↓16.3% | 43↓11.7% | 49↑1.5% | 48↑10.1% | 44 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 36↓16.3% | 43↓11.7% | 49↑1.5% | 48↑10.1% | 44 | |
| Other Expenses | -14 | 0.00↑100.0% | -3 | 0.00 | 0.00 | |
| Operating Expenses | 25↓47.1% | 48↓5.5% | 51↓3.2% | 53↑9.7% | 48 | |
| Total Costs & Expenses | 59↓11.4% | 67↓3.8% | 70↑2.3% | 68↑8.1% | 63 | |
| Operating Results | ||||||
| Operating Income | -6↑65.8% | -19↓9.2% | -17↑26.8% | -24↓63.1% | -14 | |
| Depreciation & Amortization | 0.66↑9.3% | 0.60↓13.4% | 0.69↓22.2% | 0.89↓1.4% | 0.90 | |
| EBITDA | -6↑65.5% | -17↑7.2% | -18↑17.7% | -22↓58.2% | -14 | |
| EBIT | -6↑63.0% | -17↑7.5% | -19↑17.9% | -23↓54.6% | -15 | |
| Interest & Other Income | ||||||
| Net Interest Income | -4↓4.2% | -4↓176.2% | -2↓1196.5% | 0.14↑14100.0% | 0.00 | |
| Interest Income | 1↓31.0% | 2↑74.4% | 0.92↑486.6% | 0.16↑1327.3% | 0.01 | |
| Interest Expense | 6↓5.4% | 6↑138.4% | 2↑16420.0% | 0.02↑50.0% | 0.01 | |
| Non-Operating Income | 0.00↑100.0% | -1↓193.5% | 2↑332.0% | -0.67↓284.0% | 0.36 | |
| Other Income / Expenses | -4↑1.6% | -4↓10.9% | -4↓718.0% | 0.65↑275.0% | -0.37 | |
| Income Before Tax | -11↑53.5% | -23↓9.5% | -21↑7.1% | -23↓54.6% | -15 | |
| Income Tax Expense | 0.27↑7.1% | 0.25↑110.4% | -2↓762.7% | 0.37↓3.4% | 0.38 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -11↑52.9% | -24↓25.0% | -19↑19.0% | -23↓53.1% | -15 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -11↑52.2% | -23↓25.4% | -19↑19.3% | -23↓52.8% | -15 | |
| Bottom-Line Net Income | -11↑52.2% | -23↓25.4% | -19↑19.3% | -23↓52.8% | -15 | |
| EPS (Basic) | -0.27↑59.1% | -0.66↓22.2% | -0.54↑19.4% | -0.67↓52.3% | -0.44 | |
| EPS (Diluted) | -0.27↑59.1% | -0.66↓22.2% | -0.54↑19.4% | -0.67↓52.3% | -0.44 | |
| Weighted Average Shares | 42↑18.6% | 36↑2.7% | 35↑0.3% | 35↑0.5% | 34 | |
| Weighted Average Diluted Shares | 42↑18.6% | 36↑2.7% | 35↑0.3% | 35↑0.5% | 34 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.